Isoniazid Tablets

This product is a synthetic antibacterial drug with bactericidal effect. It is only effective against mycobacteria, mainly bacteria in the growth and reproduction period. Its mechanism of action has not yet been elucidated, and it may inhibit the synthesis of mycolic acid in sensitive bacteria and cause cell wall rupture.

The main ingredient of this product is isoniazid, and its chemical name is 4-pyridinecarboxylic acid hydrazide.

This product is white tablets.

(1) Isoniazid combined with other anti-tuberculosis drugs is suitable for the treatment of various types of tuberculosis, including tuberculous meningitis and other mycobacterial infections. (2) Isoniazid alone is suitable for the prevention of various types of tuberculosis: ① Family members or close contacts of patients recently diagnosed with tuberculosis; ② Patients with a strong positive tuberculin purified protein derivative test (PPD) and a chest X-ray examination consistent with non-progressive tuberculosis, negative sputum bacteria, and no formal anti-tuberculosis treatment in the past; ③ Patients who are receiving immunosuppressants or long-term hormone therapy, certain blood diseases or reticuloendothelial system diseases (such as leukemia, Hodgkin's disease), diabetes, uremia, silicosis or gastrectomy, whose PPD test is positive; ④ Patients under 35 years old with a positive PPD test; ⑤ People who are known or suspected to be infected with HIV, whose PPD test is positive, or who have close contact with patients with active pulmonary tuberculosis.

Oral prevention: 0.3g (3 tablets) per day for adults, taken at once; 10mg/kg per day for children, not exceeding 0.3g (3 tablets) per day, taken at once. Treatment: Adults can take 5mg/kg per day orally, up to 0.3g (3 tablets) per day, or 15mg/kg per day, up to 900mg (9 tablets), 2 to 3 times a week, in combination with other anti-tuberculosis drugs. Children can take 10 to 20mg/kg per day, not exceeding 0.3g (3 tablets) per day, taken at once. For some children with severe tuberculosis (such as tuberculous meningitis), the daily dose can be as high as 30mg/kg (maximum daily dose 500mg (5 tablets)), but attention should be paid to the occurrence of liver damage and peripheral neuritis.

The more common symptoms include unsteady gait or numbness, tingling, burning or finger pain (peripheral neuritis); dark urine, yellowing of eyes or skin (hepatotoxicity, with an increased incidence of hepatotoxicity in patients over 35 years old); poor appetite, abnormal fatigue or weakness, nausea or vomiting (prodromal symptoms of hepatotoxicity). The rarest symptoms include blurred vision or decreased vision, with or without eye pain (optic neuritis); fever, rash, hematopoiesis and male breast development. This product may occasionally cause convulsions due to neurotoxicity.

It is contraindicated for patients with abnormal liver function, mental illness and epilepsy.

Precautions for children: Use strictly according to the dosage and usage for children. Precautions for pregnancy and lactation: 1. This product can cross the placenta, resulting in a higher fetal blood concentration than the maternal blood concentration. Animal experiments have confirmed that isoniazid can cause stillbirth, but although it has not been confirmed in humans, pregnant women must fully weigh the pros and cons when using it. The effect of isoniazid on the fetus when combined with other drugs has not yet been clarified. In addition, adverse reactions should be closely observed when using the drug in newborns. 2. The concentration of isoniazid in breast milk can reach 12 mg/L, which is similar to the blood concentration; although it has not been confirmed to be a problem in humans, the pros and cons should still be fully weighed when used during lactation. If the drug is used, breastfeeding should be stopped. Precautions for the elderly: The incidence of hepatitis caused by this product is higher in patients over 50 years old.

1. Drinking alcohol every day while taking isoniazid can easily cause liver toxicity induced by this product and accelerate the metabolism of isoniazid. Therefore, the dosage of isoniazid needs to be adjusted and signs of liver toxicity need to be closely observed. Patients should be advised to avoid alcoholic beverages during medication. 2. Aluminum-containing antacids can delay and reduce the absorption of isoniazid after oral administration, reducing blood drug concentrations. Therefore, it is necessary to avoid taking both at the same time, or take isoniazid at least 1 hour before oral antacids. 3. When anticoagulants (such as coumarin or indandione derivatives) are used simultaneously with isoniazid, the anticoagulant effect is enhanced due to the inhibition of the enzyme metabolism of the anticoagulant. 4. When taken together with cycloserine, adverse reactions of the central nervous system (such as dizziness or drowsiness) may be increased. The dosage needs to be adjusted and signs of central nervous system toxicity need to be closely observed, especially for patients who are engaged in work that requires high sensitivity. 5. When rifampicin is used in combination with isoniazid, the risk of hepatotoxicity may increase, especially in patients with existing liver damage or those who are fast acetylated by isoniazid. Therefore, the first three months of treatment should be closely followed up for signs of hepatotoxicity. 6. Isoniazid is an antagonist of vitamin B6, which can increase the amount of vitamin B6 excreted by the kidneys, thus possibly causing peripheral neuritis. The requirement for vitamin B6 increases when taking isoniazid. 7. When used in combination with adrenal cortical hormones (especially prednisolone), it can increase the metabolism and excretion of isoniazid in the liver, resulting in a decrease in the latter's blood concentration and affecting the efficacy, which is more significant in fast acetylated patients, and the dose should be adjusted appropriately. 8. When used in combination with alfentanil, since isoniazid is a liver enzyme inhibitor, it can prolong the effect of alfentanil; when used in combination with disulfiram, it can enhance its central nervous system effects, causing dizziness, incoordination, irritability, insomnia, etc.; when used in combination with enflurane, it can increase the formation of inorganic fluorine metabolites with nephrotoxicity. 9 When used in combination with ethionamide or other anti-tuberculosis drugs, the adverse reactions of the latter two may be aggravated. When used in combination with other hepatotoxic drugs, the hepatotoxicity of this product may be increased, so it should be avoided as much as possible. 10 Isoniazid should not be used in combination with ketoconazole or miconazole, because the blood concentrations of the latter two may be reduced. 11 When used in combination with phenytoin sodium or aminophylline, the metabolism of the two in the liver may be inhibited, resulting in an increase in the blood concentration of phenytoin sodium or aminophylline. Therefore, when isoniazid is used successively or in combination with the two, the dose of phenytoin sodium or aminophylline should be appropriately adjusted. 12 When used in combination with acetaminophen, isoniazid can induce hepatic cytochrome P-450, increasing the amount of toxic metabolites formed by the former, which may increase hepatotoxicity and renal toxicity. 13 When used simultaneously with carbamazepine, isoniazid can inhibit its metabolism, increase the blood concentration of carbamazepine, and cause toxic reactions; carbamazepine can induce the microsomal metabolism of isoniazid, resulting in an increase in the formation of hepatotoxic intermediate metabolites. 14 This product should not be used in combination with other neurotoxic drugs to avoid increasing neurotoxicity.

Keep away from light, sealed and stored in a dry place.

0.1g

36 months

JiangSu Ruinian Qianjin Pharmaceutical Co., Ltd.

• Founded in:

  1979-11-20

• Address:

  Chuanbu Village, Dingshu Town, Yixing City

• Tax NO.:

  91320282142846159Q

• Registered Funds:

  31 million yuan

• Email:

  Log in to view